Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1316 participants.

Also called NCT07307235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,316 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07307235
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07307235. Randomized; no masking; primary purpose treatment. Start 2025-12-13 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Intervention (Drug)
iGlarLixi (insulin glargine/lixisenatide)
Intervention (Drug)
standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
Lead sponsor
Shanghai Zhongshan Hospital (class: other)
Collaborator
Sanofi (China) Investment Co., Ltd (class: not stated)

Record details

Record id
cardio:ct-nct07307235
Content hash
8af87215261df9172d58858a40caa69d13bc71638d00735ce98965d57582fbad